Options Data for US Stocks: End-of-Day and Historical Learn more

MannKind Corp icon

MannKind Corp (MNKD NASDAQ) stock market data APIs

$3.8363 0.07(1.8%)
as of November 20, 2026
Try our APIs with free plan!

MannKind Corp Financial Data Overview

Price chart is built with Anychart

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. The company's commercial products include Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes; Furoscix, a formulation of furosemide injection to treat edema in pediatric patients and adult patients with chronic heart failure or chronic kidney disease; and V-Go, a mechanical basal-bolus insulin delivery system, which provides continuous subcutaneous infusion of insulin in adults that require insulin. It also developed Tyvaso DPI inhalation powder for the treatment of pulmonary arterial hypertension, as well as for the treatment of pulmonary hypertension associated with interstitial lung disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701 that focuses on bumetanide. It has collaboration and license agreement with United Therapeutics Corporation; collaboration agreement with Thirona Bio, Inc. to evaluate the therapeutic for the treatment of pulmonary fibrosis; and licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere for weight management. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Prev. Close 3.8363
Open 3.904
High 4.0672
Low 3.8005
52 wk Range 2.23-6.51
Market Cap 1 238 M
Shares Outstanding 322 M
Revenue 413 M
EPS -0.07
Beta 1.092

* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.


ETFs with MannKind Corp (top by weight)

Ticker
100-day Price Change
Weight
SBIO.US ALPS Medical Breakthroughs ETF
-15.97 (-23.86%)
0.89
QQQS.US Invesco NASDAQ Future Gen 200 ETF
-11.56 (-25.79%)
0.64
FYC.US First Trust Small Cap Growth AlphaDEX® Fund
-20.06 (-16.24%)
0.55
AGNG.US Global X Aging Population ETF
0.6 (1.56%)
0.43
JSMD.US Janus Henderson Small/Mid Cap Growth Alpha ETF
-15.85 (-16.31%)
0.33
XBI.US SPDR® S&P Biotech ETF
-16.68 (-10.63%)
0.30
FYX.US First Trust Small Cap Core AlphaDEX® Fund
-16.1 (-11.08%)
0.13
ACSG.US American Century Small Cap Growth Insights ETF
-8.75 (-17.28%)
0.12

* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.


Why to choose EODHD?

Prices start at $19.99

24/7 Live support

Robust, powerful and reliable data

API Simplicity of a few lines of code


Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW

Get MannKind Corp data using free add-ons & libraries


Get MannKind Corp Fundamental Data

MannKind Corp logo

MannKind Corp Fundamental data includes:

  • Net Revenue: 413 M
  • EBITDA: -1 942 000
  • Earnings Per Share: 0
  • Income Statements
  • Balance Sheets
  • Cash flows

Plans with Fundamental data

Starting from

$ 59.99 /mo.
COMPARE PLANS

End-of-day & Earnings data

Get MannKind Corp Earnings data

Corporate Events Calendar & News package for

$ 19.99 /mo.

What’s included:

  • Latest Release: 2026-11-05
  • EPS/Forecast: -0.08
GET THE PACKAGE

Get MannKind Corp End-of-day data

EOD Historical Data package for

$ 19.99 /mo.

What’s included:

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
GET THE PACKAGE

MannKind Corp News

Get MannKind Corp fresh news feed via Financial News API

Corporate Events Calendar & News package for

$19.99/mo.

Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW
  • Flexibility: No long-term commitments, just a minimum of one month
  • Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.

What’s included:

  • API Calls per Day: 100 000/day
  • API Requests per Min.: 1000/minute
  • Type of Usage: Personal use

Data access:

Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.

GET THE PACKAGE

Send the request

Leave your email and our team will contact you ASAP.